At ADMdx, we’re applying advances in image measurement, analysis, and AI to support earlier, more accurate identification of brain disorders, including Alzheimer’s disease and other dementias.
CorInsights® MRI, our first FDA 510k cleared product, is powered by ADMdx technology. This advanced reporting tool uses readily available MRI brain scans to support medical professionals in providing a new standard of care.
ADMdx provides a full spectrum of imaging CRO services for CNS imaging trials using PET and MRI biomarkers, including:
We support clinical trial success by combining key elements of CLARITY, QUALITY, PARTNER FOCUS, and INSIGHT.
Using our reference database and multivariate image classification, we address critical questions to support trial success:
Using our reference database of tens of thousands of PET and MRI scans with associated clinical and fluid biomarker data and through long-standing collaborations with thought leaders from major institutions, ADMdx has characterized the effects of diseases and syndromes, including: